Articles tagged with Cancer Patients
The new volume uses a health equity approach to focus on factors associated with cancer disparities research and identifies potential solutions. Studies highlight the impact of lifestyle on breast cancer risk and link mammary gland development to breast cancer disparity.
A comprehensive proteomic analysis of 103 Chinese patients with lung adenocarcinoma revealed molecular characteristics associated with clinical outcomes and potential prognostic biomarkers. The study identified 27 potential plasma biomarkers and several drug targets for LUAD, providing new insights into the disease.
Scientists have discovered that a steroidal sex hormone, ecdysone, drastically alters intestinal stem cell behavior, affecting gut growth and function. The study found that ecdysone stimulates stem cell growth and causes the gut to grow in size, leading to changes in its structure and function.
A clinical trial is underway to test an immune booster, IMM-101, in cancer patients to prevent severe COVID-19. The study aims to boost the innate immune system and protect vulnerable populations from lung infections.
A new study by Beth Israel Deaconess Medical Center found that surgical delays of 30-40 days are associated with shorter survival times in patients with colon cancer. For pancreatic and gastric cancers, the results indicate that longer surgical delays may increase cancer progression and worsen patient outcomes.
A new patient-focused intervention, DISCO App, has been developed to improve patient-provider treatment cost discussions and related patient outcomes. The five-year grant-funded study will evaluate the effectiveness of the app in reducing financial toxicity among cancer patients.
A study using electronic health records found that AI can predict who is at higher risk of pancreatic cancer up to 20 months before diagnosis. The model could help narrow down the number of people needed to be screened, potentially reducing false positives and improving survival rates.
A new study shows that genomic mutation testing using the Idylla automated system can reduce wait times for test results from 15 days to just 5 days. This allows patients to begin treatment for colorectal cancer sooner.
Researchers developed a machine learning predictive model to predict nephrotoxicity risk in testicular cancer patients using Danish patient data. The model correctly predicted 67% of high-risk patients and 92% of low-risk patients who did not develop nephrotoxicity.
A new study found that Black patients with early-stage esophageal cancer are less likely to receive life-saving surgery, contributing to their higher mortality rates. The study, which analyzed data from over 60,000 patients, suggests that education and targeted interventions are needed to address these disparities.
A new study from Memorial Sloan Kettering Cancer Center found that patients with active cancer treatment who develop COVID-19 illness do not fare any worse than other hospitalized patients. The study, published in Nature Medicine, suggests that no one should delay cancer treatment due to concerns about the virus.
A new international trial published in the Journal of Clinical Oncology suggests that carboplatin-paclitaxel is the optimal chemotherapy regimen for treating inoperable anal cancer. The study found a trend toward improved survival and less toxicity compared to cisplatin-5FU, with overall survival rates of 20 months vs 12.3 months.
PATRIOT analysis uses organoids to identify potential therapeutic targets in tumor cells, providing a holistic assessment of patient tumors. This allows for improved therapy recommendations and expanded personalized therapy options for cancer patients.
A new study found that patients' quality of life during the pandemic was significantly lower than a reference group, mainly due to social and cognitive functioning. Cancer patients considered postponing or abandoning treatment due to fear of COVID-19 morbidity and cancer progression.
A recent study by the University of Texas M. D. Anderson Cancer Center found that greater inactivity is independently associated with a higher risk of dying from cancer. Replacing sedentary time with physical activity, such as 30 minutes of cycling or walking, can lower this risk.
The InterAAct trial found carboplatin-paclitaxel to be the optimal chemotherapy regimen for inoperable anal cancer, with a lower risk of adverse events and improved overall survival. Patients treated with this regimen experienced a trend towards better survival rates, suggesting it should become the standard of care.
A patient-personalized sequencing pipeline, INVAR, enhances the sensitivity of circulating tumor DNA (ctDNA) detection in plasma samples. This technique analyzes hundreds of patient-specific mutations to detect ctDNA, enabling more accurate monitoring and potentially early relapse spotting.
Researchers discovered a novel combination of biomarkers from baseline tumor tissues that predict improved clinical responses and prolonged survival in patients with advanced bladder cancer. ARID1A mutations and CXCL13 expression were associated with better overall survival, suggesting potential patient selection improvements.
Researchers from the University of South Australia suggest that Vitamin D could mitigate chemotherapy-induced intestinal mucositis by suppressing inflammation and enhancing T-cell function. The study highlights the potential benefits of Vitamin D in reducing damage to the gut microbiome caused by chemotherapy agents.
This study evaluated the relationship between preoperative Geriatric Nutritional Risk Index and long-term outcomes in elderly gastric cancer patients. The results showed that the GNRI is a useful prognostic indicator for estimating overall survival, cancer-specific survival, and postoperative outcomes.
The study found that patients treated with chemotherapy had a significantly increased risk of dying from COVID-19, while those on anticoagulants and corticosteroids also faced higher mortality risks. In contrast, immunotherapies showed no increased risk of mortality.
A new Australian-developed treatment decision model, dubbed AUS-rule, has allowed more young cancer patients to recover from mild infections at home. The rule considers platelet and white cell counts and chemotherapy intensity to guide doctors in deciding whether patients can be treated and supported at home.
Researchers found that skeletal muscles release interleukin-15, which helps to settle and activate T-cell precursors. This enables the immune system to fight chronic infections over long periods. Regular training may strengthen the immune system by increasing muscle mass.
A randomised clinical trial has shown that a chemotherapy combination of carboplatin and paclitaxel is more effective and better tolerated than previously recommended treatments for patients with advanced anal cancer. The study found that these patients lived seven months longer overall, experiencing less treatment side effects.
Researchers at Hollings Cancer Center found a strong association between elevated AGEs in the body and breast cancer risk, particularly among women consuming high-AGE diets. The study's results suggest that reducing AGE intake through healthier food choices and physical activity may help lower cancer risk.
A study combining 15 observational studies with 9,500 patients compared the risk of cancer recurrence and death associated with minimally invasive versus open radical hysterectomy for early-stage cervical cancer. The results showed no significant difference in overall survival between the two groups.
Ashion Analytics has been certified for the National Cancer Institute's MATCH program, offering a comprehensive genomic analysis of all possible cancer mutations in DNA and RNA. This allows for personalized treatment options and potentially life-changing outcomes.
A new AI-driven system called ModGraProDep has been developed to predict cancer survival and risk. This innovative tool uses probabilistic modeling and machine learning to provide personalized predictions for patients, enabling more effective treatment planning and improved patient outcomes.
A randomized trial of a hospice video educational tool found that patients who viewed the video were more likely to prefer hospice at end-of-life and had longer hospice use compared to those receiving verbal descriptions. Caregivers also reported greater knowledge and preferences for hospice care after viewing the video.
Recent studies by Hollings Cancer Center researcher Chanita Hughes-Halbert highlight the importance of effective chronic disease prevention and management for male minority prostate cancer patients and veterans. The research emphasizes the need for better training programs and social determinants-based approaches to address underlying ...
Researchers found that 40.2% of advanced cancer patients experienced functional impairment upon hospitalization, leading to longer stays and worse outcomes. Interventions addressing this issue could enhance care delivery and outcomes for highly symptomatic patients.
Oncology pharmacy practitioners worldwide are struggling with limited and restricted PPE supply, making it difficult for them to provide high-quality cancer care. In a study, half of the surveyed countries reported impaired access to essential medications, including anti-infective agents and anticancer medications.
Researchers found that blocking Bruton tyrosine kinase (BTK) protein with acalabrutinib reduced inflammation and improved breathing in patients with severe COVID-19. The study suggests a potential new treatment approach for hospitalized patients with low blood-oxygen levels and evidence of inflammation.
Researchers at Dartmouth Health have found that HPV vaccines effective in the US may not provide adequate protection for women in low- and middle-income countries due to differing prevalence of HPV strains. This has significant implications for cervical cancer prevention and treatment in these regions.
Researchers discovered that cancer cells generate a high number of errors when copying their DNA under treatment, fuelling resistance. Combining targeted therapy with DNA repair mechanism-targeting drugs may lead to more effective therapeutic strategies.
A new study led by Ohio State University researchers has identified a protein within immune cells called PCBP1 that helps shape optimal immune responses to cancer. Higher PCBP1 activity promotes cytotoxic T-cell functions, while lower levels trigger the expression of factors that suppress cancer immune responses.
A large international trial found that pembrolizumab more than doubled the progression-free survival time of patients with a specific subtype of advanced bowel cancer, compared to chemotherapy. The treatment also showed durable benefits, with 48.3% of patients experiencing no disease progression after two years.
Researchers found that patients in Huntsman at Home had reduced hospitalizations, emergency department visits, and cumulative charges compared to controls. The study demonstrated strong evidence for the care model, showing improved patient outcomes while improving value.
A Phase II clinical trial has demonstrated a 46.5% objective response rate to tepotinib in patients with advanced non-small cell lung cancer and the MET exon 14 skipping mutation. The study's findings provide a new treatment option for this elderly population, with a durable response lasting almost one year.
A phase III clinical trial has shown that immunotherapy drug 'avelumab' significantly improves survival in patients with the most common type of bladder cancer. Treatment with avelumab resulted in a 31% reduction in risk of death and extended median survival by over seven months.
A multinational consortium reports that people with cancer have a higher risk of dying from COVID-19, particularly those with active cancer and impaired performance status. The study found no association between cancer treatments and 30-day mortality, suggesting that these therapies can continue during the pandemic with caution.
Oncologists are calling for more time spent on education about palliative care and discussing 'bad news' with patients. Research shows cancer doctors have limited coaching in this area, which can impact patient preferences for treatment or palliative care.
Researchers identified WWP1 mutations as a genetic driver of PTEN hamartoma tumor syndrome-associated cancer. The study found that WWP1 variants lead to abnormal activation of the enzyme inhibiting PTEN function and contributing to cancer development, suggesting a new therapeutic target.
A new app calculates individualized mortality risk assessment for cancer patients receiving immediate versus delayed treatment. The OncCOVID app draws on global cancer and coronavirus data to create personalized assessments, providing doctors with a tool to balance treatment needs against COVID-19 risks.
Dana-Farber nurse-scientists have received major research grants to develop innovative smoking cessation programs and study the causes of chemotherapy-induced peripheral neuropathy. The projects aim to improve lung health and treatment outcomes for cancer patients.
The dose-adjusted (DA) EPOCH-R regimen was found to be highly effective and better tolerated than standard chemotherapy for adults with Burkitt lymphoma. The treatment was effective across age groups, including patients in their 70s and 80s, and regardless of HIV status.
Researchers have found that genetic mutations from birth can promote cancer metastasis, with a single gene variant ApoE4 associated with slower tumor growth and better immune response. This discovery may lead to personalized treatment approaches for patients based on their genetics.
A study found that breast cancer survivors underutilize recommended strategies for reducing fatigue, despite high prevalence and persistence. The analysis also revealed differences in utilization of physical activity and supportive care depending on the type of fatigue experienced.
A key cell signaling pathway drives cancer-associated muscle loss, and targeting this pathway with a drug like GKT137831 could prevent cachexia. The study found that restoring SIRT1 levels can prevent muscle degeneration and extend the life of mice with pancreatic cancer
During the COVID-19 pandemic, bladder cancer patients with low-risk tumors can be safely managed with active surveillance, while those with high-risk tumors should proceed with active treatment. For muscle-invasive bladder cancer, radical cystectomy with urinary diversion is recommended.
The University of South Australia has received a $2.7 million grant to further develop anti-bacterial technologies for medical devices, building on existing successes in diagnostics and prognostics. The project aims to create nanotechnology-inspired solutions to improve patient outcomes and reduce infections.
A Monash University study found that inhibiting cell death pathways in oocytes allows them to rapidly repair DNA damage, maintaining fertility. Double-strand breaks are the most harmful type of DNA damage, promoting genetic instability if not repaired correctly.
Researchers at Hollings Cancer Center have developed a novel flow cytometry technique to quantify protein production in T-cells. This study reveals that T cells with robust protein production are more effective at controlling tumor growth.
A new study by The Institute of Cancer Research reveals that delays in cancer surgery due to the Covid-19 pandemic could result in thousands of additional deaths. The modelling suggests that a three-month delay would lead to an additional 4,755 deaths and 92,214 years of life lost.
Researchers developed TransPRECISE to combine molecular data, drug profiling, and cancer cell lines to understand tumor behavior. The tool accurately predicted potential therapeutic efficiency of drugs and identified key targets.
A review of lung cancer treatments for patients with COVID-19 was published to assist oncologists in addressing the challenges presented by these patients. The guidelines balance risk of exposure and infection with effective care, taking into account existing comorbidities.
A new study estimates that approximately one in ten people in the US with symptoms caused by major vascular events, infections, or cancers will be misdiagnosed. The study found that these conditions are among the most frequently misdiagnosed, resulting in significant harm and disability.
A clinical trial led by Mount Sinai researchers showed that combining chemotherapy and immunotherapy can significantly delay the progression of metastatic bladder cancer. The trial also found that immunotherapy alone may be an option for patients with high PD-L1 protein expression in their tumors.
A recent NIH-funded project explores how the fear of cancer recurrence affects the well-being and relationships of breast cancer patients and their spouses. The research team, led by Jean-Philippe Laurenceau, will focus on three main health behaviors that can be influenced by recurrence fears.
Researchers developed prediction tools to identify patients at risk of delayed post-operative radiotherapy, which can improve survival rates. The nomograms consider individualized risk factors and stage 4 cancer as key variables associated with delays.